PlainRecalls
FDA Drug Moderate Class II Terminated

RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.

Reported: September 4, 2019 Initiated: August 14, 2019 #D-1845-2019

Product Description

RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.

Reason for Recall

Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.

Details

Recalling Firm
Pfizer Inc.
Units Affected
a) 20,117 cartons; b) 2,502 cartons
Distribution
Nationwide in the USA and Puerto Rico.
Location
New York, NY

Frequently Asked Questions

What product was recalled?
RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY 10017.. Recalled by Pfizer Inc.. Units affected: a) 20,117 cartons; b) 2,502 cartons.
Why was this product recalled?
Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.
Which agency issued this recall?
This recall was issued by the FDA Drug on September 4, 2019. Severity: Moderate. Recall number: D-1845-2019.